Moe Alsumidaie

Ken Shimokawa, Founder and General Partner of G4S Capital, shares insights into what venture capitalists look for when evaluating emerging biopharmaceutical opportunities.

Gabe Musso, Chief Scientific Officer of BioSymetrics, talks about insights around how AI and ML are being used in biopharma.

Travis Mickle, CEO of KemPharm, talks about his company’s use of prodrugs, the business opportunities prodrugs represent, and how prodrugs are helping to improve patient centricity.

SCYNEXIS CEO, Marco Taglietti, talks about efforts to help advance fungal disease treatments.

In this Q&A, Hugh McTavish, CEO of Squarex and IGF-Oncology, shares with Pharm Exec his perspectives on running both enterprises and the medical products each is developing.

In this Q&A, Seth Lederman, CEO of Tonix Pharmaceuticals, shares key learnings for Tonix’s recent clinical trials and how they are using their expertise to provide relief to unmet patient populations.

Spiro Rombotis, president and CEO of Cyclacel, highlights why targeting cyclin-dependent kinases and the DNA repair pathway could improve the standard of care across multiple oncology indications.

Shawn Singh, CEO of VistaGen Therapeutics’, discusses the company’s pipeline of new generation drug candidates for depression, neuropathic pain, Parkinson’s dyskinesia, social anxiety disorder, and suicidal ideation with potential for convenient, at-home use, rapid-onset therapeutic benefits, and exceptional safety.

In this Q&A, Athersys CEO, Gil Van Bokkelen, PhD, discusses his perspective on the recent advancements in stem cell therapies.

A Q&A that discusses challenges of biopharmaceutical entrepreneurship in the oncology indication and the opportunities for successful therapeutic development.

Health care companies going public were reported at record levels last year, with pharma and biotech firms leading the way.

An interview with Brian Zietsman, CFO of Enteris, to discuss his strategy and how it is diversifying drug development risk, and increasing valuation.

The importance of digital engagement in the biopharma industry continues to be influenced by advancements in the technology industry as well as changes in patient needs.

The recent Pharma Customer Experience Summit explored the changing ways that patients are searching for medical information. Moe Alsumidaie highlights the takeaways.